Showing results (271-280 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 1, 1988
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinomaP Y Holoye, D T Carr, H M Dhingra, et al.
Investigational New Drugs|September 1, 1988
Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapyM McCabe, F P Smith, J S Macdonald, et al.
Investigational New Drugs|April 7, 2018
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancerYoshihisa Nakatani, Hisato Kawakami, Masashi Ichikawa, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
Investigational New Drugs|September 3, 2016
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastomaSarah B Whittle, Kalyani Patel, Linna Zhang, et al.
Investigational New Drugs|August 27, 2016
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategySamer Tabchi, Hampig Raphael Kourie, Joseph Kattan
Investigational New Drugs|August 28, 2016
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancerNoboru Yamamoto, Yutaka Fujiwara, Kenji Tamura, et al.
Investigational New Drugs|February 1, 1991
Phase II trial of cisplatin and etoposide in patients with metastatic melanomaO Eton, D F Bajorin, P B Chapman, et al.
Investigational New Drugs|February 1, 1991
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinomaS K Williamson, M Slavik
Investigational New Drugs|April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.
Pageof 372